



Date: 02nd September, 2021.

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir,

Ref : Script Id "BAJAJHCARE", Script Code "539872".
Sub : Business Updates- Bajaj Healthcare Limited to start commercial production at Plot no. N 92, MIDC, Tarapur of "Nimesulide API".

In terms of Regulation 30 of SEBI (LODR) Regulations, 2015, please find attached herewith business updates- Bajaj Healthcare Limited to start commercial production at Plot no. N 92, MIDC, Tarapur (one of the manufacturing unit acquired under SARFAESI Act, 2002 from Saraswat Bank), of "Nimesulide API".

Kindly take the same on record.

Thanking you,

For and on behalf of Board of Directors of
Bajaj Healthcare Limited

A handwritten signature in black ink, appearing to read 'Aakash Keshari'.

Aakash Keshari
Company Secretary

BAJAJ HEALTHCARE LIMITED

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.

• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com

CIN No.: L99999MH1993PLC072892



CIN: L99999MH1993PLC072892

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1, Rd No.23, Wagle Ind. Estate Thane West, Maharashtra – 400604.

BHL to start its commercial production at Plot no. N 92, MIDC, Tarapur (one of the manufacturing unit acquired under SARFAESI Act, 2002 from Saraswat Bank)

Thane, 02nd September, 2021: Bajaj Healthcare Limited (BHL) a leading manufacturer of APIs, Intermediates and Formulations, has announced to start commercial production of *Nimesulide API* at Plot No. N-92, MIDC, Tarapur. “Nimesulide API” used for relief from pain and prevention of fever. BHL has received approval from FDA Maharashtra (India), to manufacture and market “**Nimesulide API**” as approved medication for pain relief and prevention of fever in India and will commence its commercial production from tomorrow onwards.

In FY21, the Company has acquired stressed assets from the Saraswat Cooperative Bank under SARFAESI Act, 2002, which comprises of three manufacturing units and one engineering unit at MIDC, Tarapur and having installed capacity of 111 MT per month. BHL has received an approval to start its commercial production in one of the manufacturing unit acquired under SARFAESI Act, 2002 at Plot No. N-92, MIDC, Tarapur.

Commenting on the “commencement of commercial production at Plot no. N 92, MIDC, Tarapur ”, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said “*We are pleased to start of commercial production at one of the manufacturing unit acquired under SARFAESI Act, 2002 from Saraswat Bank i.e. at Plot no. N 92, MIDC, Tarapur. This manufacturing unit has Installed Capacity of 40 MT/ p.m. BHL will start commercial production of Nimesulide API from tomorrow onwards at Plot no. N 92, MIDC, Tarapur .*

FDA Maharashtra (India), has granted permission to manufacture and sales the “**Nimesulide API**” in the domestic as well as in overseas market.

About Bajaj Healthcare Limited

Bajaj Healthcare Limited a leading manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specializes in manufacturing of of Amino Acids, Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, of which 6 units are dedicated to APIs, 2 units to Intermediates and 1 unit for formulation. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.

For further information on the Company, please visit www.bajajhealth.com

Rupesh Nikam (CFO)

Bajaj Healthcare Limited

Contact: +91 22 6617 7400

Email: investors@bajajhealth.com

Krunal Shah/ Vinayak Shirodkar

Captive IR Strategic Advisors Pvt. Ltd.

Contact: +91 98922 88895

Email: krunal@cap-ir.com / Vinayak@cap-ir.com

Disclaimer:

CERTAIN STATEMENTS IN THIS DOCUMENT MAY BE FORWARD LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES LIKE GOVERNMENT ACTIONS, LOCAL POLITICAL OR ECONOMIC DEVELOPMENTS, TECHNOLOGICAL RISKS, AND MANY OTHER FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTEMPLATED BY THE RELEVANT FORWARD-LOOKING STATEMENTS. BAJAJ HEALTHCARE LTD WILL NOT BE IN ANY WAY RESPONSIBLE FOR ANY ACTION TAKEN BASED ON SUCH STATEMENTS AND UNDERTAKES NO OBLIGATION TO PUBLICLY UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT SUBSEQUENT EVENTS OR CIRCUMSTANCE